Acidmath Digest

Smoking Psychedelic Toad Milk Could Alleviate Depression For Up To 4 Weeks
May 26, 2019

Smoking Psychedelic Toad Milk Could Alleviate Depression For Up To 4 Weeks


 

A study published in the journal Psychopharmacology reported that psychedelic toad milk could be the most powerful depression remedy.

Namely, smoking the milky, psychoactive secretion of the Colorado River toad, or Bufo alvarius, is a powerful and fast alternative for managing depression.

This “toad” is popular for its poisonous secretions that can kill predators and get humans high. The biggest native toad in the United States can reach up to 7 inches in length and has the unusual ability to obtain water by osmotic absorption through its abdomen.

The North American toad excretes a whiteish substance which is rich in a compound called 5-MeO-DMT, a variation of DMT, which is also found in the mild-altering psychedelic brew ayahuasca.

According to researchers, when dried and smoked, the “toad milk” creates a short but potent psychedelic experience, and as the ego dissolves, one supposedly receives mystical insights.

They maintain that a single inhalation of vapor from dried toad secretion containing 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting can cause sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.

 

 

Read more →

LSD IS HELPING PEOPLE END THEIR ALCOHOL DEPENDENCE
May 21, 2019

LSD IS HELPING PEOPLE END THEIR ALCOHOL DEPENDENCE


 

A newly published study suggests that consuming LSD or magic mushrooms may help people overcome alcohol dependency — yet another exciting development in the burgeoning field of psychedelics research.

“There’s incredible potential here,” Johns Hopkins University researcher Matthew Johnson told Inverse. “So far, it’s a good bet that these tools will be broadly applicable to a number of disorders.”

For the study, which was published Tuesday in The Journal of Psychopharmacology, the researchers used social media and drug discussion websites to track down 343 people who reported a minimum of seven years of problematic drinking prior to having a psychedelic experience.

They then asked the participants — 72 percent of whom met the criteria for alcohol use disorder — to complete anonymous online surveys.

From the surveys, the researchers learned many participants had dramatically decreased the number of drinks they consumed a year after their psychedelic experience. In fact, 83 percent of participants no longer met alcohol use disorder criteria, and 28 percent credited their psychedelic experience for the change in lifestyle

It’s hard to demonstrate a direct link between the psychedelic experience and the decrease in alcohol consumption. However, Johnson thinks it makes sense that mind-opening drugs could have a positive impact on the lives of people battling alcohol dependence.

“When you talk to someone who has managed to overcome addiction, they often talk about [how] they had to answer big picture questions that connect to what’s important in life,” he told Inverse. “Psychedelics prompt those kinds of questions.”

Source: FUTURISM.


Read more →

Why 'Microdosing' LSD & Other Hallucinogens May Be The Saving Grace For People With Severe Depression & Anxiety
April 30, 2019

Why 'Microdosing' LSD & Other Hallucinogens May Be The Saving Grace For People With Severe Depression & Anxiety

 

What if your brain on acid, 'shrooms and Molly isn't such a bad thing after all?

Many might consider lysergic acid diethylamide (LSD), also known as "acid", taboo (and possibly even passé), yet the currently illegal and unregulated drug is rapidly gaining popularity, as well as media scrutiny and attention within the medical community.

The widespread illegality of these substances means little scientific data exists regarding their potential short and long-term positive or negative effects on either mental of physical health, but this time around, the trendy way of dropping acid and other hallucinogenics such as psilocybin "magic" mushrooms and 3,4-Methyl​enedioxy​methamphetamine (MDMA, aka "Molly" or "ecstasy") involves a practice called "microdosing."

rong>As one report in Scientific American explains:

"Microdosing involves taking roughly one-tenth the 'trip' dose of a psychedelic drug, an amount too little to trigger hallucinations but enough, its proponents say, to sharpen the mind. Psilocybin microdosers (including hundreds on Reddit) report that the mushrooms can increase creativity, calm anxiety, decrease the need for caffeine, and reduce depression."

 

 

Georgia (not her real name) was nine years old when her father was murdered.

Even at that young age, she says, “I hit a really hard trauma wall and I never really came out of it.”

She was consumed with anger, went four months without speaking, and had a severe depressive episode at 13.

The now 29-year-old, who works at a Washington, D.C. nonprofit, was diagnosed with persistent depressive disorder (dysthymia) — defined as a "continuous, long-term (chronic) form of depression" — four years ago.

At the time, she was prescribed the antidepressant Wellbutrin, a norepinephrine-dopamine reuptake inhibitor (NDRI), which was effective in treating her depression. But after she left her job and lost her health insurance, she could no longer afford prescription medication.

 

Read the full article here: YOURTANGO.COM

 

Read more →

Study: Psychedelic Found In Toad Venom Helps Relieve Depression, Anxiety
March 23, 2019

Study: Psychedelic Found In Toad Venom Helps Relieve Depression, Anxiety

BALTIMORE — Forget meditation or standard medicine. A new study finds that a psychedelic found in toad venom may help people struggling with depression or anxiety.

Research conducted at the Johns Hopkins University School of Medicine shows the fast-acting psychedelic, 5-MeO-DMT (it currently lacks a marketable household name), helped relieve symptoms in about 80 percent of the 362 study participants who tried it in a group setting. The authors believe the short duration of psychedelic effects make it a more favorable therapy for patients.

“Research has shown that psychedelics given alongside psychotherapy help people with depression and anxiety. However, psychedelic sessions usually require 7 – 8 hours per session because psychedelics typically have a long duration of action,” says co-author Alan K. Davis, a postdoctoral research fellow with the university’s Behavioral Research Unit, in a release. “Because 5-MeO-DMT is short-acting and lasts approximately 30-90 minutes, it could be much easier to use as an adjunct to therapy because current therapies usually involve a 60 – 90 minute session.”

Patients reported greater feelings of life satisfaction and well-being, and also reported a more spiritual experience during the treatment.

5-MeO-DMT is found in the venom of the Bufo Alvarius toad (also known as The Colorado River toad), as well as in some plants, but scientists have been able to produce it synthetically. Prior research by Davis has shown the substance has a low risk for health and legal consequences.

“It is important to examine the short- and long-term effects of 5-MeO-DMT, which may enhance mood in general or may be particularly mood enhancing for those individuals experiencing clinically significant negative mood,” says Davis. “Regardless, this research is in its infancy and further investigation is warranted in healthy volunteers.”

The study was published in The American Journal of Drug and Alcohol Abuse.

 

<a href="https://cbdfx.com/ref/104/" title="CBDfx.com"><img src="https://cbdfx.com/wp-content/uploads/2018/10/CBDfx-970x250.jpg" alt="CBDfx.com" /></a>

Read more →

Highly Accredited Doctor States “MDMA Not Too Dangerous”
March 21, 2019

Highly Accredited Doctor States “MDMA Not Too Dangerous”

 

The debate over whether or not MDMA is dangerous has been going on for decades. It has gone as far as whether it should be legalized, or if there should be pill testing centers at festivals. It has been looked down upon by society due to the numerous deaths the drug has caused. But on the other side, recent studies have shown MDMA may actually have positive medical effects. Specialist GP David Charles Thomas weighed in on the debate that is central to so many countries.

According to the doctor, the drug is “not that dangerous” when taken in “pure form.” The real danger lies in the illegal market that the drug functions in. People don’t know what they are taking and its almost impossible to tell. He said all this on a podcast called “Triggered.” The GP went into how the drug causes self-excitement but at the same time limits an individuals ability to self-regulate their temperature.

“IT CAN MAKE THEM FEEL LIKE THEY HAVE A LOT MORE ENERGY, BUT IT ALSO DECOUPLES THEIR TEMPERATURE REGULATION AND THEIR PERCEPTION TO THE EXTENT OF ANY WARNING SIGNS.”

The podcast centralized around the debate over pill testing in Australia, something not really debated here in the states. There have been many deaths at festivals over the past two years and the public wants some form of pill testing. As the debate rages on some parties have discussed the potential for passing a bill for testing. However, it would most likely need to be seen that the drug has positive medical uses. Similar to how marijuana has become legal.

At the end of the day, even if bills like this don’t pass, people should still be testing their pills at home. It is better to be safe and remember to stay hydrated.

Source: Edtumes.

 

CBDfx.com

Read more →

Psilocybin- Smoking cessation, OCSD, and End of Life Anxiety
October 01, 2016

Psilocybin- Smoking cessation, OCSD, and End of Life Anxiety

Art-by-Pineal-Visions

Johns Hopkins researchers report that a few longtime smokers quit after a carefully controlled and monitored use of psilocybin in the context of a cognitive behavioural therapy treatment program. The abstinence rate for study participants was 80 percent after six months. It is not that quitting smoking is a simple biological reaction to psilocybin,  but more precisely when administered after careful preparation and in a therapeutic context, psilocybin can lead to deep reflection regarding one's life and spark motivation to change.


Not only is psilocybin being looked at carefully for smoking cessation, but as well, treating OCD/Eating Disorders, and Reducing anxiety and depression levels in Cancer patients. At the Heffter Zürich Research Center, a close examination of serotonin 5-HT2A neuroreceptor dynamics in the human brain following the administration of psilocybin, and its potential relevance for the treatment of obsessive-compulsive spectrum disorders (OCSDs), including OCD and eating disorders is under way. [2]


With CS Grob behind the helm, we have the first psychedelic treatment with terminally ill patients since the early 1970s. Grob and colleagues performed a pilot study of the effect of psilocybin on 12 patients with advanced-stage cancer and a diagnosis of acute stress disorder, generalized anxiety disorder, anxiety disorder due to cancer or adjustment disorder with anxiety. [3] Psilocybin did not cause any clinically significant adverse effects. It caused a significant decrease in anxiety, as assessed by the State-Trait Anxiety Inventory at one and three months after treatment, and improved mood, as measured by the Beck Depression Inventory after six months. [3] However, in a follow-up assessment at 8-16 months of 90 healthy people who received psilocybin in experimental studies, seven participants reported they had experienced negative changes in well-being due to the psilocybin. [4]

 

A lot of attention goes to treating cancer, but not treating the person dying from cancer. Psilocybin is being used to help the patient move into a positive mental state, thus these kinds of studies on an ethical level is sound, as they look to treat the whole human being.

.

 

Sources

 

1. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Johnson MW1, Garcia-Romeu A2, Cosimano MP2, Griffiths RR3.

 

2. http://www.heffter.org/research-hz.htm

 

3. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–8.

 

4. Studerus E, Kometer M, Hasler F, et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol.

Art: mushrooms_by_rodulfo-oil-on-canvas-november-2007

Read more →